metastic and recurrance breast cancer
Conditions
Sponsors
Toho University Omori Medical Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Histologically confirmed Breast cancer 2.Inoperative metastatic or recurrent breast cancer 3.Patients with evaluable lesion 4.Age >=20 5.No prior treatment for metastatic or recurrent breast cancer 6.Sufficient organ functions Hemoglobin >=9.0g/dl WBC >=4000/mm3 Neurtophils >=2000/mm3 Platelets >=100,000/mm3 Total bilirubin <=1.5mg/dl GOT and GPT < ULNx2.5 Creatinine <1.5mg/dl 7.Performance status 0-1 8.Patients who have passed the following periods from previous treatment Endocrinetherapy:7 days from the final administration Adjuvant:6 months from the final administration 9Written IC
Exclusion criteria
Exclusion criteria: 1.Inflammatory and bilateral breast cancer 2.Active another cancer 3.History of hypersensitivity reaction 4. Other severe complications, such as pulmonary emphysema or pulmonary fibrosis, uncontrollable diabetes, heart failure, renal insufficiency, liver failure 5.Neuropathy <= grade1 6. Radiation therapy for chest 7.Serious myeloablation 8.Infection 9.Pregnant or possibility pregnancy or nursing woman 10.Physician judged improper to entry this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response Rate | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS,OS,Safty | — |
Countries
Japan
Contacts
Public ContactSyunsuke Magoshi
Toho University Omori Medical Center Breast and Endocrine Surgery
Outcome results
None listed